N,N,3'-trimethyl-[1,1'-biphenyl]-3-amine | 81722-82-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N,N,3'-trimethyl-[1,1'-biphenyl]-3-amine
• 英文别名: N,N-dimethyl-3-(3-methylphenyl)aniline
• CAS: 81722-82-9
• 化学式: C₁₅H₁₇N
• 分子量: 211.307
• InChiKey: ZECORSQSRFTGNB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.73
• 重原子数：
  16.0
• 可旋转键数：
  2.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  3.24
• 氢给体数：
  0.0
• 氢受体数：
  1.0

反应信息

• 作为产物：
  描述：

  N,N-二甲基间苯二胺 在 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 48.61h， 生成 N,N,3'-trimethyl-[1,1'-biphenyl]-3-amine
  参考文献：
  名称：

  NHC镍催化单保护苯胺的C–N键裂解，实现C–C交叉偶联

  摘要：

  已经开发了单保护的苯胺（N-芳基磺酰胺）的Ni催化的芳基C–N键裂解。一种新的衍生自苯并咪唑的N杂环卡宾对C–N裂解/ CC交叉偶联反应具有高反应活性。的邻位不要求导向基团打破磺酰基-保护的苯胺，这不限于π扩展苯胺的C-N键。机理研究表明，磺酰胺基镁盐是关键的偶联中间体。

  DOI：

  10.1021/acs.orglett.0c03660

文献信息

• 4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-3,6-DIHYDROPYRIDINE-1-(2H)-CARBOXAMIDE DERIVATIVES AS LIMK AND/OR ROCK KINASES INHIBITORS FOR USE IN THE TREATMENT OF CANCER
  申请人：Centre National de la Recherche Scientifique

  公开号：EP3915990A1

  公开（公告）日：2021-12-01

  The present invention concerns a compound of formula (I), in particular as LIMK and/or ROCK kinases inhibitors. The present invention also concerns these new inhibitors for use for the treatment of a condition selected in the group consisting of: cancers, virion infections, ocular hypertension and glaucoma formation, Neurofibromatosis type 1 and 2, psoriatic lesions, inflammatory diseases and hyperalgesia, central sensitization and chronic pain, reproduction erectile dysfunction, and neuronal diseases. The present description discloses the syntheses and characterisation of exemplary compounds as well as pharmacological data thereof (e.g. pages 32 to 127; examples 1 to 96; families 1 to 8; compounds; biological studies; tables). An exemplary compound is e.g. 4-(5-m ethyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-N-phenyl-3,6-dihydropyridine-1-(2H)-carboxamide (example 1; compound 5).

  本发明涉及一种化合物，特别是作为LIMK和/或ROCK激酶抑制剂的化合物（I）的公式。本发明还涉及这些新抑制剂的用途，用于治疗所选组中的疾病，包括：癌症、病毒感染、眼压增高和青光眼形成、神经纤维瘤病1和2型、银屑病损、炎症性疾病和过敏症、中枢敏化和慢性疼痛、生殖勃起功能障碍和神经疾病。本说明披露了示例化合物的合成和表征，以及其药理学数据（例如第32至127页；示例1至96；家族1至8；化合物；生物学研究；表格）。一个示例化合物是4-(5-甲基-7H-吡咯并[2,3-d]嘧啶-4-基)-N-苯基-3,6-二氢吡啶-1-(2H)-甲酰胺（示例1；化合物5）。
• Brune, Hans Albert; Ertl, Josef; Grafl, Dieter, Chemische Berichte, 1982, vol. 115, # 3, p. 1141 - 1153
  作者：Brune, Hans Albert、Ertl, Josef、Grafl, Dieter、Schmidtberg, Guenter

  DOI：——

  日期：——
• [EN] 4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-3,6-DIHYDROPYRIDINE-1-(2H)-CARBOXAMIDE DERIVATIVES AS LIMK AND/OR ROCK KINASES INHIBITORS FOR USE IN THE TREATMENT OF CANCER<br/>[FR] DÉRIVÉS DE 4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-3,6-DIHYDROPYRIDINE-1-(2H)-CARBOXAMIDE SERVANT D'INHIBITEURS DE KINASES LIMK ET/OU ROCK DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DU CANCER
  申请人：CENTRE NAT RECH SCIENT

  公开号：WO2021239727A1

  公开（公告）日：2021-12-02

  The present invention concerns a compound of formula (I), in particular as LIMK and/or ROCK kinases inhibitors. The present invention also concerns these new inhibitors for use for the treatment of a condition selected in the group consisting of: cancers, virion infections, ocular hypertension and glaucoma formation, Neurofibromatosis type 1 and 2, psoriatic lesions, inflammatory diseases and hyperalgesia, central sensitization and chronic pain, reproduction erectile dysfunction, and neuronal diseases. The present description discloses the syntheses and characterisation of exemplary compounds as well as pharmacological data thereof (e.g. pages 37 to 163; examples 1 to 169; compounds; biological studies; tables; figure pages 1/6 to 6/6). An exemplary compound is e.g. 4-(5-methyl-7H-pyrrolo[2,3- d]pyrimidin-4-yl)-N-phenyl-3,6-dihydropyridine-1-(2H)-carboxamide (example 1; compound 5).